Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11-Dehydrosinulariolide is a bioactive cembranolide diterpene isolated from the cultured soft coral *Sinularia flexibilis*. It has demonstrated significant anti-tumor activity in preclinical models, particularly against small cell lung cancer (SCLC), oral squamous cell carcinoma, and melanoma. The compound exerts its effects by inducing G2/M phase cell cycle arrest and triggering apoptosis through multiple pathways. Key mechanisms include the activation of the DNA damage response via the ATM/Chk2 pathway, upregulation of p53 and Bax, and activation of caspases-3 and -7. Additionally, it promotes the accumulation of the tumor suppressor PTEN, which subsequently inhibits the Akt signaling pathway, further suppressing tumor cell proliferation and survival.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11-dehydrosinulariolide.